MiRNAs as biomarkers and therapeutic targets in cancer

Current Opinion in Pharmacology

Volumn 10, Issue 5, 2010, Pages 543-550

  Heneghan, Helen M ^a   Miller, Nicola ^a   Kerin, Michael J ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

2' O METHYL ANTI MICRORNA OLIGONUCLEOTIDE; ANTISENSE OLIGONUCLEOTIDE; ANTIVIRUS AGENT; MESSENGER RNA; MICRORNA; MICRORNA 181B; MICRORNA 200; MICRORNA 21; MICRORNA 221; MICRORNA 222; MICRORNA 23; MICRORNA 24; MICRORNA 27; MICRORNA 34; MICRORNA 342; MICRORNA 34A; MICRORNA 489; PROTEIN LET 7; SPC 3649; TAMOXIFEN; TUMOR MARKER; UNCLASSIFIED DRUG;

APOPTOSIS; BIOGENESIS; BREAST CANCER; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER THERAPY; CARCINOGENESIS; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CLINICAL TRIAL; COLORECTAL CANCER; EARLY DIAGNOSIS; GENE EXPRESSION; GENE FUNCTION; GENE TARGETING; HEPATITIS C; HUMAN; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; REVIEW; TUMOR XENOGRAFT;

DRUG DELIVERY SYSTEMS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; INDIVIDUALIZED MEDICINE; MICRORNAS; NEOPLASMS; ONCOGENES; TUMOR MARKERS, BIOLOGICAL;

EID: 77956652041     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2010.05.010     Document Type: Review

References (41)

1. Garcia M., Jemal A., Ward E., Center M., Hao Y., Siegel R., Thun M. Global Cancer Facts & Figures 2007 2007, American Cancer Society.
2. Lowery A.J., Miller N., McNeill R.E., Kerin M.J. MicroRNAs as prognostic indicators and therapeutic targets: potential effect on breast cancer management. Clin Cancer Res 2008, 14:360-365.
3. Miranda K.C., Huynh T., Tay Y., Ang Y.S., Tam W.L., Thomson A.M., Lim B., Rigoutsos I. A pattern-based method for the identification of MicroRNA binding sites and their corresponding heteroduplexes. Cell 2006, 126:1203-1217.
4. Bartel D. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
5. Jackson R.J., Standart N. How do microRNAs regulate gene expression?. Sci STKE 2007, 2007:re1.
6. Metias S.M., Lianidou E., Yousef G.M. MicroRNAs in clinical oncology: at the crossroads between promises and problems. J Clin Pathol 2009, 62:771-776.
7. Calin G.A., Dumitru C.D., Shimizu M., Bichi R., Zupo S., Noch E., Aldler H., Rattan S., Keating M., Rai K., et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002, 99:15524-15529.
8. Lu J., Getz G., Miska E.A., Alvarez-Saavedra E., Lamb J., Peck D., Sweet-Cordero A., Ebert B.L., Mak R.H., Ferrando A.A., et al. MicroRNA expression profiles classify human cancers. Nature 2005, 435:834-838.
9. Volinia S., Calin G.A., Liu C.G., Ambs S., Cimmino A., Petrocca F., Visone R., Iorio M., Roldo C., Ferracin M., et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006, 103:2257-2261.
10. Iorio M.V., Ferracin M., Liu C.G., Veronese A., Spizzo R., Sabbioni S., Magri E., Pedriali M., Fabbri M., Campiglio M., et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005, 65:7065-7070.
11. Mattie M.D., Benz C.C., Bowers J., Sensinger K., Wong L., Scott G.K., Fedele V., Ginzinger D., Getts R., Haqq C. Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol Cancer 2006, 5:24.
12. Lowery A.J., Miller N., Devaney A., McNeill R.E., Davoren P.A., Lemetre C., Benes V., Schmidt S., Blake J., Ball G., et al. MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer. Breast Cancer Res 2009, 11:R27.
13. Heneghan H.M., Miller N., Newell J., Lowery A.J., Sweeney K.J., Kerin M.J. Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg 2010, 251:499-505.
14. Iorio M.V., Casalini P., Tagliabue E., Menard S., Croce C.M. MicroRNA profiling as a tool to understand prognosis, therapy response and resistance in breast cancer. Eur J Cancer 2008, 44:2753-2759.
15. Pasquinelli A.E., Reinhart B.J., Slack F., Martindale M.Q., Kuroda M.I., Maller B., Hayward D.C., Ball E.E., Degnan B., Muller P., et al. Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. Nature 2000, 408:86-89.
16. Takamizawa J., Konishi H., Yanagisawa K., Tomida S., Osada H., Endoh H., Harano T., Yatabe Y., Nagino M., Nimura Y., et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 2004, 64:3753-3756.
17. Yanaihara N., Caplen N., Bowman E., Seike M., Kumamoto K., Yi M., Stephens R.M., Okamoto A., Yokota J., Tanaka T., et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006, 9:189-198.
18. Rabinowits G., Gercel-Taylor C., Day J.M., Taylor D.D., Kloecker G.H. Exosomal microRNA: a diagnostic marker for lung cancer. Clin Lung Cancer 2009, 10:42-46.
19. Schetter A.J., Leung S.Y., Sohn J.J., Zanetti K.A., Bowman E.D., Yanaihara N., Yuen S.T., Chan T.L., Kwong D.L., Au G.K., et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 2008, 299:425-436.
20. Wang P., Zou F., Zhang X., Li H., Dulak A., Tomko R.J., Lazo J.S., Wang Z., Zhang L., Yu J. microRNA-21 negatively regulates Cdc25A and cell cycle progression in colon cancer cells. Cancer Res 2009, 69:8157-8165.
21. Asangani I.A., Rasheed S.A., Nikolova D.A., Leupold J.H., Colburn N.H., Post S., Allgayer H. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 2008, 27:2128-2136.
22. Ng E.K., Chong W.W., Jin H., Lam E.K., Shin V.Y., Yu J., Poon T.C., Ng S.S., Sung J.J. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 2009, 58:1375-1381.
23. Akao Y., Nakagawa Y., Naoe T. MicroRNA-143 and -145 in colon cancer. DNA Cell Biol 2007, 26:311-320.
24. Braun C.J., Zhang X., Savelyeva I., Wolff S., Moll U.M., Schepeler T., Orntoft T.F., Andersen C.L., Dobbelstein M. p53-Responsive micrornas 192 and 215 are capable of inducing cell cycle arrest. Cancer Res 2008, 68:10094-10104.
25. He X., He L., Hannon G.J. The guardian's little helper: microRNAs in the p53 tumor suppressor network. Cancer Res 2007, 67:11099-11101.
26. Sun T., Wang Q., Balk S., Brown M., Lee G.S., Kantoff P. The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines. Cancer Res 2009, 69:3356-3363.
27. Mitchell P.S., Parkin R.K., Kroh E.M., Fritz B.R., Wyman S.K., Pogosova-Agadjanyan E.L., Peterson A., Noteboom J., O'Briant K.C., Allen A., et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008, 105:10513-10518.
28. Seto A.G. The road toward microRNA therapeutics. Int J Biochem Cell Biol 2010.
29. Krutzfeldt J., Rajewsky N., Braich R., Rajeev K.G., Tuschl T., Manoharan M., Stoffel M. Silencing of microRNAs in vivo with 'antagomirs'. Nature 2005, 438:685-689.
30. Si M.L., Zhu S., Wu H., Lu Z., Wu F., Mo Y.Y. miR-21-mediated tumor growth. Oncogene 2007, 26:2799-2803.
31. Elmen J., Lindow M., Schutz S., Lawrence M., Petri A., Obad S., Lindholm M., Hedtjarn M., Hansen H.F., Berger U., et al. LNA-mediated microRNA silencing in non-human primates. Nature 2008, 452:896-899.
32. Elmen J., Thonberg H., Ljungberg K., Frieden M., Westergaard M., Xu Y., Wahren B., Liang Z., Orum H., Koch T., et al. Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality. Nucleic Acids Res 2005, 33:439-447.
33. Elmen J., Lindow M., Silahtaroglu A., Bak M., Christensen M., Lind-Thomsen A., Hedtjarn M., Hansen J.B., Hansen H.F., Straarup E.M., et al. Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. Nucleic Acids Res 2008, 36:1153-1162.
34. Haussecker D, Kay MA: miR-122 continues to blaze the trail for microRNA therapeutics. Mol Ther 2010, 18:240-242.
35. Ebert M.S., Neilson J.R., Sharp P.A. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat Methods 2007, 4:721-726.
36. Johnson C.D., Esquela-Kerscher A., Stefani G., Byrom M., Kelnar K., Ovcharenko D., Wilson M., Wang X., Shelton J., Shingara J., et al. The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res 2007, 67:7713-7722.
37. Fujita Y., Kojima K., Hamada N., Ohhashi R., Akao Y., Nozawa Y., Deguchi T., Ito M. Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells. Biochem Biophys Res Commun 2008, 377:114-119.
38. Weidhaas J.B., Babar I., Nallur S.M., Trang P., Roush S., Boehm M., Gillespie E., Slack F.J. MicroRNAs as potential agents to alter resistance to cytotoxic anticancer therapy. Cancer Res 2007, 67:11111-11116.
39. Kato M., Paranjape T., Muller R.U., Nallur S., Gillespie E., Keane K., Esquela-Kerscher A., Weidhaas J.B., Slack F.J. The mir-34 microRNA is required for the DNA damage response in vivo in C. elegans and in vitro in human breast cancer cells. Oncogene 2009, 28:2419-2424.
40. Miller T.E., Ghoshal K., Ramaswamy B., Roy S., Datta J., Shapiro C.L., Jacob S., Majumder S. MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem 2008, 283:29897-29903.
41. Heneghan H.M., Miller N., Lowery A.J., Sweeney K.J., Kerin M.J. MicroRNAs as novel biomarkers for breast cancer. J Oncol 2009, 2009:950201.